NASDAQ:AVRO

AVROBIO Stock Forecast, Price & News

$14.39

-0.55 (-3.68 %)

(As of 01/15/2021 12:00 AM ET)

Add

Compare

Today's Range

$14.28

Now: $14.39▼

$15.29

50-Day Range

$12.82

MA: $14.22▼

$15.75

52-Week Range

$9.76

Now: $14.39▼

$29.32

Volume738,263 shs

Average Volume237,277 shs

Market Capitalization$524.52 million

P/E RatioN/A

Dividend YieldN/A

Beta1.41

AVROBIO, Inc., a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease. The company's lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02 that has completed pre-clinical trials for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; and AVR-RD-04 that has completed pre-clinical studies for treating cystinosis. The company has a research and clinical collaboration agreement with Magenta Therapeutics to evaluate targeted antibody-drug conjugate as a conditioning regimen for lentiviral gene therapies. AVROBIO, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

MarketRank^™

Overall MarketRank^™

1.67 out of 5 stars

Medical Sector

199th out of 1,556 stocks

Biological Products, Except Diagnostic Industry

20th out of 143 stocks

3.4 Analyst's Opinion

Consensus Rating
AVROBIO has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $32.17, AVROBIO has a forecasted upside of 123.5% from its current price of $14.39.
Amount of Analyst Coverage
AVROBIO has only been the subject of 3 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
AVROBIO has received 149 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
AVROBIO has received 127 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
AVROBIO has received 53.99% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about AVROBIO and other stocks. Vote “Outperform” if you believe AVRO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AVRO will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
AVROBIO does not currently pay a dividend.
Dividend Growth
AVROBIO does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AVROBIO insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.78% of the stock of AVROBIO is held by insiders.
Percentage Held by Institutions
86.71% of the stock of AVROBIO is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for AVROBIO are expected to grow in the coming year, from ($3.45) to ($3.36) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AVROBIO is -4.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of AVROBIO is -4.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
AVROBIO has a P/B Ratio of 2.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:AVRO

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.avrobio.com

Phone617-914-8420

Employees123

Debt

Debt-to-Equity RatioN/A

Current Ratio9.14

Quick Ratio9.14

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$5.87 per share

Price / Book2.45

Profitability

EPS (Most Recent Fiscal Year)($2.66)

Net Income$-72,960,000.00

Net MarginsN/A

Return on Equity-51.33%

Return on Assets-47.65%

Miscellaneous

Outstanding Shares36,450,000

Market Cap$524.52 million

Next Earnings Date3/15/2021 (Estimated)

OptionableNot Optionable

$14.39

-0.55 (-3.68 %)

(As of 01/15/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive AVRO News and Ratings via Email

Sign-up to receive the latest news and ratings for AVRO and its competitors with MarketBeat's FREE daily newsletter.

AVROBIO (NASDAQ:AVRO) Frequently Asked Questions

How has AVROBIO's stock been impacted by COVID-19?

AVROBIO's stock was trading at $18.02 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AVRO stock has decreased by 20.1% and is now trading at $14.39.
View which stocks have been most impacted by COVID-19.

Is AVROBIO a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVROBIO in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AVROBIO stock.
View analyst ratings for AVROBIO or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than AVROBIO?

Wall Street analysts have given AVROBIO a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but AVROBIO wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is AVROBIO's next earnings date?

AVROBIO is scheduled to release its next quarterly earnings announcement on Monday, March 15th 2021.
View our earnings forecast for AVROBIO.

How were AVROBIO's earnings last quarter?

AVROBIO, Inc. (NASDAQ:AVRO) announced its quarterly earnings data on Tuesday, November, 10th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.81) by $0.20.
View AVROBIO's earnings history.

What price target have analysts set for AVRO?

7 analysts have issued twelve-month target prices for AVROBIO's stock. Their forecasts range from $13.00 to $43.00. On average, they expect AVROBIO's share price to reach $32.17 in the next twelve months. This suggests a possible upside of 123.5% from the stock's current price.
View analysts' price targets for AVROBIO or view Wall Street analyst' top-rated stocks.

Who are some of AVROBIO's key competitors?

Some companies that are related to AVROBIO include Bavarian Nordic A/S (BVNRY), Replimune Group (REPL), Scholar Rock (SRRK), REGENXBIO (RGNX), Vericel (VCEL), Translate Bio (TBIO), C4 Therapeutics (CCCC), NantKwest (NK), BioCryst Pharmaceuticals (BCRX), Forma Therapeutics (FMTX), Inhibrx (INBX), Atara Biotherapeutics (ATRA), Alector (ALEC), Cellectis (CLLS) and Vaxcyte (PCVX).
View all of AVRO's competitors.

What other stocks do shareholders of AVROBIO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AVROBIO investors own include Sorrento Therapeutics (SRNE), ImmunoGen (imgn), Aduro Biotech (ADRO), Aldeyra Therapeutics (ALDX), Amarin (AMRN), Biohaven Pharmaceutical (BHVN), Nabriva Therapeutics (NBRV), Selecta Biosciences (SELB), VBI Vaccines (vbiv) and Arbutus Biopharma (ABUS).

Who are AVROBIO's key executives?

AVROBIO's management team includes the following people:

Mr. Geoff MacKay, Co- Founder, Pres, CEO & Director (Age 54, Pay $746.7k)
Mr. Erik Ostrowski, CFO & Treasurer (Age 47, Pay $739.58k)
Mr. Steven N. Avruch J.D., Chief Legal Officer & Sec. (Age 59, Pay $441.68k)
Mr. Jeffrey Medin Ph.D., Scientific Founder
Mr. Matthew Arnold, Head of Operations
Mr. Kim Raineri M.B.A., Chief Manufacturing & Technology Officer
Mr. Chris Mason, Chief Scientific Officer
Ms. Monique Da Silva, Sr. VP of Corp. Communications
Ms. Georgette Verdin, Chief HR Officer
Ms. Deanna M. Petersen, Chief Bus. Officer (Age 58)

When did AVROBIO IPO?

(AVRO) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush Securities was co-manager.

What is AVROBIO's stock symbol?

AVROBIO trades on the NASDAQ under the ticker symbol "AVRO."

How do I buy shares of AVROBIO?

Shares of AVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AVROBIO's stock price today?

One share of AVRO stock can currently be purchased for approximately $14.39.

How big of a company is AVROBIO?

AVROBIO has a market capitalization of $524.52 million. The company earns $-72,960,000.00 in net income (profit) each year or ($2.66) on an earnings per share basis. AVROBIO employs 123 workers across the globe.

What is AVROBIO's official website?

The official website for AVROBIO is www.avrobio.com.

How can I contact AVROBIO?

AVROBIO's mailing address is ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-914-8420 or via email at [email protected]

This page was last updated on 1/17/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here